The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for managing obesity. Unlike some available weight loss approaches, retatrutide appears to provide a more substantial reduction in body mass and improve metabolic markers, particularly c